Finding antibodies to protect against Crimean-Congo Hemorrhagic Fever
Isolation of broadly protective monoclonal antibodies for Crimean Congo Hemorrhagic Fever
This study is looking at how to use antibodies from people who have survived Crimean-Congo Hemorrhagic Fever to help protect others from the virus, and it’s for anyone interested in finding new ways to fight this serious illness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10981217 on NIH RePORTER |
What this research studies
This research focuses on Crimean-Congo Hemorrhagic Fever (CCHF), a serious viral infection with no current vaccine or specific treatment. The team aims to isolate monoclonal antibodies from survivors of CCHF, which may provide broad protection against the virus. By analyzing blood samples from CCHF survivors in Turkey, they will identify antibodies that can neutralize the virus effectively. The research will also test these antibodies in a mouse model to evaluate their protective capabilities.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have survived Crimean-Congo Hemorrhagic Fever.
Not a fit: Patients who have not been infected with Crimean-Congo Hemorrhagic Fever are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments for CCHF, potentially saving lives.
How similar studies have performed: Previous research has shown promise in isolating protective antibodies from survivors of viral infections, indicating potential success for this approach.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — University of Maryland Baltimore
- Study coordinator: Sajadi, Mohammad Mohseni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.